ABSTRACT
Myelosuppression is a toxicity-related limitation for aranoza dosage. The drug proved effective in the treatment of uterine sarcoma, cancer of the head and neck, breast, Hodgkin's disease and lymphosarcoma during stage II of clinical studies. Complete regression was reported in the treatment of melanoma (ca. 12%). Good results of chemoimmunotherapy should be expected in untreated patients as well as intraarterial infusions for local lesions of the extremities. Clinical trials of aranoza used in combined modalities of therapy in various sites continue.
Subject(s)
Antineoplastic Agents/therapeutic use , Glycosides/therapeutic use , Interferon-alpha/therapeutic use , Melanoma/drug therapy , Methylnitrosourea/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Drug Therapy, Combination , Glycosides/administration & dosage , Glycosides/adverse effects , Humans , Infusions, Intra-Arterial , Interferon-alpha/administration & dosage , Methylnitrosourea/administration & dosage , Methylnitrosourea/adverse effects , Methylnitrosourea/analogs & derivatives , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Time FactorsABSTRACT
Phase-I clinical studies of teraphtal and a "teraphtal + ascorbic acid" catalytic system have been completed. The dose-limiting toxicity and maximum tolerable dose were not reached even at the end of maximal dose trials. No side-effects characteristic of antitumor cytostatic drugs were registered. The gravest side-effect ever recorded was a collapse which could not be linked to teraphtal dosage and was probably caused by hypersensitivity to the drug. The drug was recommended for phase II trials.
Subject(s)
Antineoplastic Agents/therapeutic use , Indoles/therapeutic use , Adrenal Gland Neoplasms/drug therapy , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Breast Neoplasms/drug therapy , Colonic Neoplasms/drug therapy , Female , Humans , Indoles/administration & dosage , Indoles/adverse effects , Kidney Neoplasms/drug therapy , Male , Melanoma/drug therapy , Middle Aged , Sarcoma/drug therapy , Skin Neoplasms/drug therapy , Soft Tissue Neoplasms/drug therapyABSTRACT
Material is presented on combined effects of mm-band radio waves and cyclophosphane on the hemopoietic system and inoculated tumor sarcoma-180. The role of the bone marrow truncal cells in the acceleration of regenerative processes and a two-fold increase of clonogenic activity of the bone marrow were determined in the combined group in comparison with the bone marrow of animals receiving just the preparation. The sensitizing effect of mm-waves in combination with cyclophosphane was distinctly manifested after two courses of administration of the preparation, leading to 85-100% resorption of the tumours without further relapses during the year of observation over the animals.
Subject(s)
Cyclophosphamide/therapeutic use , Hematopoiesis/drug effects , Microwaves/therapeutic use , Animals , Bone Marrow/drug effects , Bone Marrow/physiopathology , Bone Marrow/radiation effects , Colony-Forming Units Assay , Combined Modality Therapy , Drug Evaluation, Preclinical , Hematopoiesis/radiation effects , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Neoplasm Transplantation , Sarcoma 180/physiopathology , Sarcoma 180/therapy , Time FactorsSubject(s)
Magnetics , Animals , Biological Clocks , Mice , Motor Activity/physiology , Muscles/physiology , Space Flight , Time FactorsABSTRACT
An exposure of mice to a constant magnetic field (CMF) of 9.9, 25.4 and 39.4 kersted produced changes in the leucocyte and reticulocyte counts and caused no changes in the red blood cell count and hemoglobin. The changes noted during and after the exposure were of a cyclic pattern. During a 24-hour exposure of animals to a CMF of 39.4 kersted a short-term increase in the reticulocyte and leucocyte counts and a concomitant decrease of the neutrophil and lymphocyte counts were noted. Afterwards the reticulocyte count decreased and increased again by the end of the exposure. Following a 3-hour exposure to CMFs of the above intensities the changes persisted for 20-35 days. Normally the parameters increased during the 1-2 days of the exposure and decreased thereafter. The level of changes was not correlated with the CMF intensity. The increase in the reticulocyte count during and exposure to a CMF of 39.4 kersted was identical to that during an exposure to a CMF of I kersted.
Subject(s)
Blood Cells , Hemoglobins/analysis , Magnetics , Animals , Blood Cell Count , Erythrocytes , Leukocytes , Mice , ReticulocytesABSTRACT
It has been shown that red blood cells are sensitive to a constant magnetic field. Under this influence reticulocytosis develops whereas the hemoglobin level and red blood cell count remain unaltered. Changes in the reticulocyte content during a continuous many-day exposure to a constant magnetic field give evidence that an animal body can adapt to this effect.
